PubMed=22374462; DOI=10.1038/bjc.2012.57; PMCID=PMC3304425
Kailayangiri S., Altvater B., Meltzer J., Pscherer S., Luecke A., Dierkes C., Titze U., Leuchte K., Landmeier S., Hotfilder M., Dirksen U., Hardes J., Gosheger G., Juergens H., Rossig C.
The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.
Br. J. Cancer 106:1123-1133(2012)

PubMed=24927333; DOI=10.3892/or.2014.3269
Leuchte K., Altvater B., Hoffschlag S., Potratz J., Meltzer J., Clemens D., Luecke A., Hardes J., Dirksen U., Juergens H., Kailayangiri S., Rossig C.
Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function.
Oncol. Rep. 32:845-852(2014)

PubMed=29464090; DOI=10.18632/oncotarget.23815; PMCID=PMC5814230
Spurny C., Kailayangiri S., Altvater B., Jamitzky S., Hartmann W., Wardelmann E., Ranft A., Dirksen U., Amler S., Hardes J., Fluegge M., Meltzer J., Farwick N., Greune L., Rossig C.
T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G.
Oncotarget 9:6536-6549(2018)

PubMed=30879952; DOI=10.1016/j.ymthe.2019.02.014; PMCID=PMC6520468
Kailayangiri S., Altvater B., Lesch S., Balbach S.T., Gottlich C., Kuhnemundt J., Mikesch J.-H., Schelhaas S., Jamitzky S., Meltzer J., Farwick N., Greune L., Fluegge M., Kerl K., Lode H.N., Siebert N., Muller I., Walles H., Hartmann W., Rossig C.
EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for targeting with gene-modified T cells.
Mol. Ther. 27:933-946(2019)